Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.
The Conversation logo

From the start of the pandemic, it was clear that some people who were infected with the coronavirus were experiencing more severe illness, which increased their chances of being hospitalised, admitted to an intensive care unit (ICU) or dying.

As we age, a weaker immune system and chronic health conditions could influence the way our body responds to the virus. Indeed, age is the biggest risk factor for developing severe COVID or dying from it. Over 70% of deaths attributed to COVID in the UK are in those aged 75 years and over.

Ethnicity, sex and obesity were also found to be risk factors for severe COVID outcomes. But, of course, we can’t do anything about our age, sex or ethnicity. We can do something about being overweight, though.

Body mass index (BMI) is a measure applying height and weight to calculate a weight score. A person with a BMI over 25 is considered to be overweight, and over 30 is considered to be obese.

Read the full article on The Conversation website, co-written by Nerys M AstburyCarmen Piernas and Min Gao (Nuffield Department of Primary Care Health Sciences).

Oxford is a subscribing member of The ConversationFind out how you can write for The Conversation.

Similar stories

Major grant to strengthen research and benefit patients

Oxford University Hospitals (OUH) has made a grant of £11.5 million to the University of Oxford, which the University will match with other funding, to allow the development of major clinical research facilities which have the potential to support the introduction of innovative and ground-breaking treatments for patients.

Dr Lennard Lee awarded ACP McElwain Prize for contributions to medical oncology

Dr Lee (Department of Oncology) received the award to acknowledge his contributions during the COVID-19 pandemic, through the establishment of the UK Coronavirus Cancer Monitoring Project.

Oxford joins forces with 11 universities to launch social impact investment fund

The University of Oxford has joined forces with 11 leading universities to create Impact 12, an impact investment fund to support mission-led university ventures.

Ivermectin to be investigated as a possible treatment for COVID-19 in the PRINCIPLE trial

From today, ivermectin is being investigated in the UK as part of the Platform Randomised Trial of Treatments in the Community for Epidemic and Pandemic Illnesses (PRINCIPLE), the world’s largest clinical trial of possible COVID-19 treatments for recovery at home and in other non-hospital settings.

Potential for radiotherapy and VTP multimodality therapy for prostate cancer

A recent collaborative study from the University of Oxford has investigated the potential benefit of a combined therapy approach to prostate cancer treatment, using radiotherapy and vascular targeted photodynamic therapy (VTP), which could lead to first-in-man early phase clinical trials.

Latest data on immune response to COVID-19 reinforces need for vaccination, says Oxford-led study

A new study led by the University of Oxford has found that previous infection, whether symptomatic or asymptomatic, does not necessarily protect you long-term from COVID-19, particularly against new Variants of Concern.